Novel Discovery of LYVE-1 Expression in the Hyaloid Vascular System

Hui Zhang, Julie Tse, Xuemei Hu, Marlys Witte, Michael Bernas, Jinjoo Kang, Firehiwott Tilahun, Young-Kwon Hong, Mengseng Qiu, and Lu Chen

**Purpose.** The hyaloid vascular system (HVS) is a transient network nourishing developing eyes and has been widely used as a natural model to study blood vessel regression. Failure of its regression in humans leads to several blinding diseases. Lymphatic vessel endothelial hyaluronic acid receptor (LYVE-1) is a recently defined lymphatic marker that is also expressed by a subpopulation of macrophages. To date, there is no report on its expression in the HVS. This study was conducted to investigate whether LYVE-1 is expressed in the HVS and how it is associated with the vascular structure and macrophage phenotype.

**Methods.** Normal C57BL/6 mouse eyeballs were sampled from embryonic day (E) 10.5 to postnatal (P) and adult stages for immunofluorescent microscopic studies with antibodies against LYVE-1, CD31 (panendothelial cell marker), and F4/80 (macrophage marker). Additionally, Angiopoietin-2 (Ang-2) knockout mice with abnormally persistent HVS were examined.

**Results.** The LYVE-1 expression was detected on normal HVS between E12.5 and P14. The LYVE-1+ cells were F4/80+ but CD31−, indicating a macrophage lineage. Additionally, LYVE-1+ cells bud on CD31+ vessels and constitute an integral part of the network in both normal developing and Ang-2 knockout mice.

**Conclusions.** This study provides the first evidence that the HVS contains a LYVE-1+ cellular component in both physiological and pathologic conditions. This novel finding not only provides a new concept in defining the embryogenesis and pathogenesis of the HVS, it also leads to a completely natural model in which to study the functions of the LYVE-1 pathway, an important topic for lymphatic research as well.

**Methods**

**Animals.** Normal male and female C57BL/6 mice (Taconic Farms, Germantown, NY) were bred and maintained in the animal facilities of the University of Louisville in Kentucky and the University of Southern California. Ang-2 knockout mice of the C57BL/6 background (Regeneron Pharmaceuticals, Inc., Tarrytown, NY) were maintained in the animal facilities.
of the University of Arizona, as described previously.10 All mice were treated according to the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research and the animal protocols approved by the Animal Care and Use Committees.

Tissue Preparation

In all timed pregnancies, the plug date was designed as embryonic day (E) 0.5, and the date of birth was defined as postnatal day (P) 0. For prenatal stages, normal embryos were sampled at E10.5, E12.5, E14.5, E16.5, and E18.5; for postnatal stages, normal ocular tissues were sampled at P2, P7, P14, and 6 weeks. Ocular tissues of Ang-2 homozygous knockout and control heterozygote mice were sampled at P14. For cross-sectional studies, the specimens were immersed in OCT compound (Tissue-Tek; Sakura Finechemical, Torrance, CA) and frozen at −80°C for further studies; for whole mount assays, the specimens were fixed in 4% paraformaldehyde overnight at 4°C for further studies.

Antibodies

The following primary antibodies were used: rabbit anti–mouse LYVE-1, rat anti–mouse F4/80 (Abcam, Cambridge, MA), and rat anti–mouse CD31/PECAM-1 (BD PharMingen, San Diego, California). The isotype controls included rat IgG1, normal rabbit IgG (Abcam), and purified rat IgG2a (BD PharMingen). The secondary antibodies were FITC-conjugated donkey-anti–rabbit IgG (Santa Cruz Biotechnology, Santa Cruz, CA), Alexa488-conjugated donkey anti–rat IgG, and Cy3-conjugated donkey anti–rabbit IgG (Jackson ImmunoResearch, West Grove, PA).

Immunofluorescence Microscopic Studies

Five-micrometer frozen sections or whole mount tissues were used for immunofluorescence staining as described previously.7,11,12 Briefly, the samples were first incubated with PBS containing 3% bovine serum albumin (BSA), 3% normal donkey serum, and 0.3% Triton X-100 to reduce the staining background. Thereafter, for LYVE-1 single staining, the samples were incubated overnight at 4°C with rabbit anti–mouse LYVE-1 antibody followed by secondary antibody incubation. For sequential double-staining of LYVE-1 and CD31 or F4/80, the samples were incubated with rat anti–mouse CD31 or rat anti–mouse F4/80 antibody overnight at 4°C, followed by the incubation with secondary antibodies. These samples were then stained with rabbit anti–mouse LYVE-1 antibody at room temperature for 2 hours (sections) or at 4°C overnight (whole mounts), followed by another incubation with the secondary antibody. The samples were mounted with mounting medium (Vectashield; Vector Laboratories, Burlingame, CA) with DAPI, observed with a fluorescence microscope (Carl Zeiss, München-Hallbergmoos, Germany), and photographed with a digital camera system (Axiocam; Carl Zeiss). For each antibody staining study, tissue samples from three to five mice were examined. For cross-sectional studies, at least five sections were analyzed for each tissue sample derived from each animal. For cell quantification analysis, cells that were F4/80+/CD31− were counted.
LYVE-1 Expression with the Formation of HVS

We first investigated whether LYVE-1 is expressed in the HVS and how this expression correlates with the normal onset of this structure. Given that HVS in mice starts to form at E10.5 and becomes full-developed by E13.5, we examined LYVE-1 expression in the cross-sections of the developing vitreous cavities from E10.5 to E18.5. Results from these studies clearly demonstrated that LYVE-1 was expressed in the embryonic vitreous at E12.5 (Fig. 1C) and thereafter (Figs. 1D–F) coincided with the developing phase of the HVS. Furthermore, LYVE-1 expression was aligned around the lens and widely scattered in the primary vitreous, which is also in accordance with the HVS locations. Therefore, both the time window and the spatial location of LYVE-1 expression synchronized with the onset of the HVS during mouse embryonic stages.

LYVE-1 Expression with the Regression of HVS

To further investigate whether LYVE-1 is also expressed during the regression phase of HVS, we next studied LYVE-1 expression in the cross-sections of the vitreous cavities from P2 to P14. It is known that most HVS vessels regress during the first 2 weeks after birth in mice. As a control, the adult vitreous cavity, which should be absent from the HVS structure, was also examined. Our results from these studies further demonstrated that LYVE-1 expression gradually diminished in the postnatal vitreous cavities as the HVS regressed. As shown in Figure 2, LYVE-1 expression was obvious in the vitreous cavity at P2 (Fig. 2A) and P7 (Fig. 2B), barely detectable at P14 (Fig. 2C), and completely disappeared in the adult (Fig. 2D). The expression of LYVE-1, hence, also synchronized with the regression of HVS.

Intimate Association between the LYVE-1+ and CD31+ Cells in HVS

We and other researchers have reported previously that in addition to lymphatic vessels, LYVE-1 is also expressed in some isolated cells in normal adult ocular tissues. To further investigate whether the LYVE-1 signals we detected in the developing vitreous cavities are from the HVS vasculatures or single isolated cells, we next performed a series of double-staining assays using the specific antibodies against LYVE-1 and CD31, a pan-endothelial cell marker. Both embryonic and postnatal tissues were examined. These studies further revealed that the LYVE-1-expressing cells were CD31− at embryonic (Fig. 3A) and postnatal (Fig. 3B) stages. However, some LYVE-1+ cells appeared, abutting the CD31+ cells (Fig. 3C, left) or linearly arranged along the CD31+ branches (Fig. 3C, right). Red: LYVE-1; green: CD31; blue: DAPI nuclei staining. L, lens; V, vitreous; R, retina. Scale bars: 100 μm (A, B); 25 μm (C).

LYVE-1+ or F4/80+/LYVE-1+ were counted in the vitreous cavity for each section, and the results were presented in the percentage of the total number of F4/80+ cells.

RESULTS

LYVE-1 Expression in the Hyaloid Vascular System 6159

LYVE-1 Expression in the Hyaloid Vascular System

LYVE-1+ Cells of the Macrophage Lineage

It has been shown previously that macrophages are present in the developing vitreous cavities. To further study the relationship between the LYVE-1+ cells and the macrophages in the HVS, we next performed a series of double-staining assays using the specific antibodies against LYVE-1 and F4/80, a macrophage marker. Both embryonic and postnatal tissues were examined. Our results from these studies further demonstrated that all the LYVE-1+ cells in the HVS expressed F4/80 (Fig. 5C, arrows), denoting their macrophage lineage. An additional macrophage population that was F4/80+ positive, but LYVE-1− was also observed in these vitreous cavities (Fig. 5C, arrow.)

Intimate Association of LYVE-1+ and CD31+ Cells in HVS

A

B

C

FIGURE 3. Intimate association of LYVE-1+/CD31− cells in the HVS. (A–C) Representative cross-sectional micrographs demonstrating the intimate link between LYVE-1+ and CD31+ cells at embryonic (A) and postnatal (B) stages. (C) Higher magnification views of the boxed areas in (A) and (B), respectively. LYVE-1+ cells appeared abutting the CD31+ cells (C, left) or linearly arranged along the CD31+ branches (C, right). Red: LYVE-1; green: CD31; blue: DAPI nuclei staining. L, lens; V, vitreous; R, retina. Scale bars: 100 μm (A, B); 25 μm (C).

FIGURE 4. LYVE-1 cells as an integral part of the HVS. Whole-mount micrograph showing the LYVE-1+ cells attached to the hyaloid vasculatures. Red: LYVE-1; green: CD31. HA, hyaloid artery. Scale bar, 50 μm.
heads). Summarized data for these two cell populations are presented in Figure 5D.

LYVE-1⁺ Cells in the Persistent HVS of Ang-2 Knockout Mice

Finally, to investigate whether LYVE-1⁺ cells also accompany the HVS under a pathologic situation, such as persistent HVS, we also examined the expression of LYVE-1 in Ang-2 knockout mice. It has been reported that Ang-2 deficiency leads to a defect in HVS regression, resembling persistent fetal vasculature (PFA) in humans.15 Whole mount tissues from both Ang-2 knockout and control mice were sampled at P14 and were double stained with CD31 and LYVE-1 antibodies. As shown in Figure 6, abundant LYVE-1⁺ cells (Fig. 6A, arrowheads) were observed in the remnant CD31⁺ hyaloid vasculatures in Ang-2 knockout mice. As a comparison, no hyaloid structures were detected in the control mouse sample in which retinal vessels were well developed with sparsely distributed LYVE-1⁺ cells, as reported previously.16 These results further confirm that LYVE-1⁺ cells constitute an integral part of HVS under pathologic conditions as well.

DISCUSSION

In this study, we provide the first evidence that LYVE-1 is expressed in mouse HVS under both physiological and pathologic conditions. We have also demonstrated that LYVE-1-expressing cells are of the macrophage lineage and have an intimate association with CD31⁺ endothelial cells. Further investigation on this interesting phenomenon may provide novel information on the mechanisms and treatment of HVS diseases. Allied to this prediction are results from some earlier studies demonstrating that macrophages of the HVS are involved in the programmed vascular regression of the HVS.18,19

The expression of LYVE-1 on single cells has been reported previously.5–8,16 Our finding that LYVE-1 is expressed on the macrophage-lineage cells in the HVS is new but consistent with previous findings on other ocular7,8,16 and nonocular tissues.5,6,9 However, compared with other tissues in which LYVE-1 is expressed on single and isolated cells that are not part of any vascular structures, the hyaloid system is unique in that its LYVE-1⁺ macrophages are attached to the vessels and form an integral part of the network. Further studies are required to investigate whether the LYVE-1⁺ network is involved in the metabolism of hyaloid acid or contributes to the temporary drainage of the intraocular components in developing eyes.

Finally, from a broader perspective, this study also identifies a novel and completely natural model in which to study the functions of the LYVE-1 pathway, which may also be involved in other physiological and pathologic processes outside the eye. The LYVE-1 is a defined and the most widely used marker to identify lymphatic vessels that penetrate most tissues in the body. Lymphatic dysfunctions have been found in a wide array of disorders, including cancer metastasis, autoimmune diseases, transplant rejection, and lymphedema.16,20–24 To date, there is still little effective treatment for lymphatic diseases. It is hoped that continued studies on the LYVE-1 pathway using the unique hyaloid system may indulge novel mechanisms and
therapeutic factors to combat currently untreatable diseases inside and outside the eye.

Acknowledgments

The authors thank Jeffrey LeDue (University of California at Berkeley) for his excellent technical assistance with the immunofluorescence microscopic studies.

References